- Home
- HSCS vs ENTO Comparison
HSCS vs ENTO Comparison
Compare HSCS & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- ENTO
- Stock Information
- Founded
- HSCS 2007
- ENTO 2014
- Country
- HSCS United States
- ENTO United States
- Employees
- HSCS N/A
- ENTO N/A
- Industry
- HSCS Medical Specialities
- ENTO Biotechnology: Pharmaceutical Preparations
- Sector
- HSCS Health Care
- ENTO Health Care
- Exchange
- HSCS Nasdaq
- ENTO Nasdaq
- Market Cap
- HSCS 3.2M
- ENTO 2.9M
- IPO Year
- HSCS 2022
- ENTO 2016
- Fundamental
- Price
- HSCS $3.17
- ENTO $0.54
- Analyst Decision
- HSCS Strong Buy
- ENTO
- Analyst Count
- HSCS 2
- ENTO 0
- Target Price
- HSCS $13.50
- ENTO N/A
- AVG Volume (30 Days)
- HSCS 15.1K
- ENTO 72.4K
- Earning Date
- HSCS 03-13-2025
- ENTO 11-13-2024
- Dividend Yield
- HSCS N/A
- ENTO N/A
- EPS Growth
- HSCS N/A
- ENTO N/A
- EPS
- HSCS N/A
- ENTO N/A
- Revenue
- HSCS $14,700.00
- ENTO N/A
- Revenue This Year
- HSCS $174.19
- ENTO N/A
- Revenue Next Year
- HSCS $4,100.00
- ENTO N/A
- P/E Ratio
- HSCS N/A
- ENTO N/A
- Revenue Growth
- HSCS 151.28
- ENTO N/A
- 52 Week Low
- HSCS $2.36
- ENTO $0.19
- 52 Week High
- HSCS $18.50
- ENTO $9.35
- Technical
- Relative Strength Index (RSI)
- HSCS 39.08
- ENTO 56.47
- Support Level
- HSCS $3.11
- ENTO $0.48
- Resistance Level
- HSCS $3.45
- ENTO $0.63
- Average True Range (ATR)
- HSCS 0.17
- ENTO 0.07
- MACD
- HSCS -0.02
- ENTO 0.01
- Stochastic Oscillator
- HSCS 8.70
- ENTO 86.74
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About ENTO Entero Therapeutics Inc. Common Stock
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.